Bone Biologics Corp. reported the addition of osteoporosis and trauma indications to its portfolio.
Here are five highlights:
1. The company expanded its license agreement's Field of Use definition with the UCLA Technology Development Group for NELL-1. The agreement is on behalf of UC Regents.
2. NELL-1 is a recombinant human protein growth factor designed to help normal bone development.
3. Bone Biologics is also entering an exclusive license agreement with the UCLA Technology Development Group on behalf of UC Regents. The agreement is for the global application of the NELL-1 protein for osteoporosis and trauma via a technology transfer.
4. Current research is assessing NELL-1's ability to restore bone and prevent further loss.
5. Bone Biologics develops a bone graft substitute for spinal fusions.